Latest Asx Company Filings News

FINEOS Corporation delivered solid first-half results with revenue growth and improved profitability, while navigating currency challenges that temper full-year guidance.

WT Financial Group (ASX, WTL) reported a 20.5% rise in FY2025 net profit after tax to $4.6 million, driven by strong revenue growth and operational leverage. The company declared a fully-franked dividend of 0.7 cents per share, underpinned by its expanding B2B financial advice network and proprietary risk management framework.

Solvar Limited reported a notable 84.4% jump in net profit for FY25 even as revenue declined 6.1%, alongside a healthy dividend increase.

SPC Global Holdings Ltd has reported FY25 proforma results exceeding guidance with a normalised EBITDA of $30.3 million, setting the stage for ambitious growth and international expansion in FY26.

Clever Culture Systems Ltd has reported a remarkable 288% jump in revenue to $6.63 million for the year ended June 2025, turning around from a loss to a net profit of $1.68 million, buoyed by strong product sales and government support.

betr Entertainment Limited posts a 140% turnover increase to $1.42 billion and achieves a positive EBITDA of $7.2 million in FY25, driven by strategic mergers and market exits. The company ups its takeover bid for PointsBet, signaling aggressive consolidation ambitions.

Catalina Resources is launching a Reverse Circulation drilling program at its Laverton Gold Project to explore extensions of promising gold zones along a key structural corridor in Western Australia.

betr Entertainment Limited marked a transformative FY25 with a successful merger, strategic acquisitions, and a sharp reduction in losses, setting the stage for a major takeover bid of PointsBet.

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.